At the news
? MIXEDIMPACT 7/10 8-K filed Feb 26, 2026 at 07:37 ET
Wave Life Sciences reported a significant year-over-year decline in revenue and a shift from net income to a substantial net loss, driven by lower collaboration revenue. However, the company highlighted positive clinical progress across its pipeline, including obesity drug WVE-007 showing fat loss comparable to GLP-1s, strong data for WVE-006 in AATD, and a well-capitalized position with cash runway into 3Q 2028. The negative financials are offset by multiple upcoming clinical catalysts and pipeline advancements.
- Revenue dropped 79.7% YoY to $17.2M in Q4 2025 and 60.5% for the full year to $42.7M, primarily due to reduced GSK milestone payments.
- Net loss was $53.2M in Q4 2025 vs. $29.3M net income in Q4 2024; full-year net loss was $204.4M vs. $97.0M in 2024.
- Cash and equivalents increased to $602.1M as of Dec 31, 2025, providing runway into 3Q 2028.
- WVE-007 (obesity) showed fat loss similar to GLP-1s at three months in interim data, with muscle preservation, and plans for Phase 2a trials in 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access